Skip to main content

Posts

Showing posts from August 4, 2025

Trained ILCs confer adaptive #immunity-independent #protection against #influenza

ABSTRACT Seasonal influenza causes 290,000–650,000 deaths annually, with vaccination efficacy ranging from 10 to 60%. The emergence of drug-resistant and highly pathogenic avian influenza viruses underscores the urgent need for novel protective strategies . Epidemiological observations have long suggested that certain vaccines, such as Bacillus Calmette-GuĂ©rin (BCG), can provide protection against diverse pathogens (S. Biering-Sørensen, P. Aaby, N. Lund, et al., Clin Infect Dis 65:1183–1190, 2017, https://doi.org/10.1093/cid/cix525 ; M.-L. Garly, C. L. Martins, C. BalĂ©, et al., Vaccine 21:2782–2790, 2003, https://doi.org/10.1016/s0264-410x(03)00181-6 ; C. A. G. Timmermann, S. Biering‐Sørensen, P. Aaby, et al., Trop Med Int Health 20:1733–1744, 2015, https://doi.org/10.1111/tmi.12614 ). While the cellular and molecular mechanisms underlying such protection remain incompletely understood, emerging research offers critical insights into innate immune system modulation (B. Cirovic, L. C. J...

A randomized, double-blind, placebo-controlled trial of #niclosamide nanohybrid for #treatment of patients with mild to moderate #COVID19

Abstract Effective and reliable treatments for SARS-CoV-2 infections are a key part of global COVID-19 management . Based on vitro studies, niclosamide has been considered as a potential drug candidate for SARS-CoV-2, but its clinical development has been limited due to poor solubility and bioavailability. Here we report results from a randomized, double-blind, placebo-controlled clinical trial involving 300 patients (Clinical Trial Registration Number: KCT0007307) that assessed the efficacy and safety of the niclosamide nanohybrid CP-COV03 at two different doses. Oral CP-COV03 was well tolerated, with no serious adverse events reported in any treatment group. The primary endpoints demonstrated that CP-COV03 significantly alleviated all 12 FDA-recommended COVID-19 symptoms , with symptom improvement sustained for more than 48 h. Additionally, CP-COV03 reduced SARS-CoV-2 viral load by 56.7% within 16 h of the initial dose compared to baseline. Secondary endpoints, including time to sust...

#UK - High pathogenicity avian #influenza #H5N1 viruses (#poultry) (Inf. with) - Immediate notification

{England, Norfolk} Commercial indoor unit with 59562 turkeys. Increased mortality and other clinical signs were reported. Samples were taken and were tested positive for HPAI H5N1. Source: WOAH,  https://wahis.woah.org/#/in-review/6693 ____

#Hungary - #Influenza A #H5N1 viruses of high pathogenicity (Inf. with) (non-poultry including wild birds) (2017-) - Immediate notification

By Diliff - Own work, CC BY-SA 3.0,  https://commons.wikimedia.org/w/index.php?curid=1385555 ___ Two wild Greylag Geese in GyÅ‘r-Moson-Sopron Region. Source: WOAH,  https://wahis.woah.org/#/in-review/6687?reportId=175652&fromPage=event-dashboard-url ____